← All trials
NCT04450069
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 14, 2020
- Primary completion
- Jul 31, 2023
- Completion date
- Apr 30, 2024
- First posted
- Jun 29, 2020
- Last posted
- Dec 14, 2020
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- California Institute for Biomedical ResearchLead sponsor
- University of California, San DiegoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.